Diabetic macular oedema (DMO) is the main cause of vision loss in diabetic retinopathy. The ILUVIEN ® intravitreal implant, which contains fluocinolone acetonide and is administered by injection into the vitreous cavity, should be considered if the patient is not responding to anti-vascular endothelial growth factor (VEGF) therapy, and the patient fulfils the recommendations of the National Institute for Health and Care Excellence (NICE) Technology Appraisal 301. The efficacy and safety of the ILUVIEN implant has been demonstrated in clinical studies, and a pre-planned subgroup analysis has shown that it is particularly beneficial in patients with chronic DMO. This case study is the first report in the UK of the effectiveness of the ILUVIEN implant in a patient in whom therapy with ranibizumab did not result in sustained improvements in terms of visual outcomes and foveal thickness.
The International Diabetes Federation (IDF) estimated that 8.3 % of adults (or 382 million) had diabetes in 2013. 1 This is significantly higher than previous estimates (2.8 % or 171 million adults). 2 Diabetic retinopathy (DR) is a potentially sight-threatening disease affecting the retinal microvasculature and associated with prolonged hyperglycaemia and other conditions linked to diabetes mellitus such as hypertension. 3 DR is a chronic progressive disease with a prevalence of 34.6 %. 4 The prevalence of DR and new cases of DR varies by country with prevalence ranging from 10 % in Norway to 61 % in South Africa and newly diagnosed cases ranging from 1.5 % in African Americans to 31 % in China. 5 DR is a major cause of vision loss and blindness. Global vision loss occurs through the growth of new vessels, leading to intraocular haemorrhage and, in some cases, retinal detachment. Central vision loss is due to localised damage to the macula/fovea of the eye 3 as occurs in diabetic macular oedema (DMO) when the macula swells as fluid accumulates. DMO leads to vision loss and blindness in around 20 % of patients with DR. 5 These rates are set to rise, with diabetes set to increase to in excess of 592 million within the next 25 years. 
Pathophysiology of Diabetic Macular Oedema
Numerous physiological and molecular factors, including angiogenesis, inflammation and oxidative stress, are involved in DMO pathogenesis. 6 At early disease stages, vascular endothelial growth factor (VEGF) is a major factor in driving retinal changes whereas in chronic diseases, such as DMO, heightened inflammation plays a more important role. 7, 8 Multiple inflammatory cytokines, such as interleukin (IL)-1β, IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), interferon-gammainducible protein (IP-10) and VEGF, are upregulated as the severity of DR increases. 9 DMO is multi-factorial disease and steroids can provide an effective therapeutic option as they target multiple factors in DMO.
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The ILUVIEN Intravitreal Implant ILUVIEN is an intravitreal implant containing 190 µg of fluocinolone acetonide (FAc implant). It measures 3.5 mm in length and 0.37 mm in width, and is injected into the vitreous cavity using a 25-gauge needle.
The implant releases 0.2 µg/day of fluocinolone acetonide. 11 FAc implant is a multi-factorial therapy that offers continuous low-dose therapy for up to 36 months with a single injection. 12 The efficacy and safety of FAc implant has been examined in the Pharmacokinetic and Efficacy Study Denmark with licences pending in several other European countries.
Described here, to the best of the author's current knowledge, is the first case study reporting the UK of the effectiveness of the FAc implant in a patient in whom therapy with ranibizumab did not result in sustained improvements in terms of visual outcomes and foveal thickness.
Clinical Experience
A 68-year-old, white female with type 2 diabetes who had been Figure 2 ; **see 
Reference -7 January 2013
Follow-up -4 March 2013 ranibizumab treatment, she was listed for FAc implant injection in the LE and this was conducted 18 days later.
Response to ILUVIEN
One week after the intravitreal injection, the patient's LE VA had improved to 6/18; CMT had rapidly decreased from 774 µm to 267 µm (i.e. >500 µm improvement) and decimal vision had improved from 0.25 to 0.33. Further, after an additional 14 days, vision improved to 0.50 (6/12) . This represents a gain of 15-letters. This gain in vision was maintained at 6 months.
Five months post-FAc implant insertion, DMO resolution was maintained with stable results on OCT scanning (see Figure 4) . 
Reference -4 March 2013

Follow-up -8 April 2013
VA in the LE has improved to 6/12 (a gain of 15-letters) at the time of writing and the patient is being monitored on a quarterly basis.
Concluding Remarks
In this case study, the FAc implant swiftly induced complete regression of DMO in the LE of a patient who had ceased to respond to treatment after multiple anti-VEGF injections. FAc implant also rapidly improved vision by 15-letters and reached a vision of 6/12 after 14 days. After receiving FAc implant, the patient's vision improved to 6/12 (or 0.5) and achieving this is important to the patient as it is a requirement for a driving licence in the UK. 17 This case report includes an extended period of follow-up (6 months) and no IOP changes were identified.
This real-use clinical experience of the FAc implant in a patient who did not show an optimal response to anti-VEGF therapy is in line with the evidence reported in the FAME clinical studies. These studies investigated the efficacy and safety of the FAc implant, and pre-planned subgroup analysis revealed that the relative benefit was most substantial in patients with chronic DMO. 15 This is the first report of the FAc implant following prior therapy with anti-VEGF therapy and a siRNA agent. The management of this case study was carried out in accordance with the guidance outlined in the NICE Technology Appraisal 301. 16 No side effects of the FAc implant were reported in this case; however, the most common side effects reported in the ILUVIEN Summary of Product Characteristics include cataract operation, cataract, increased intraocular pressure and floaters. 11 The FAc implant represents an important treatment option that should be considered in a patient who is not responding to anti-VEGF therapy. In such patients, treatment with FAc implant should not be delayed, as the ultimate goal of any treatment for DMO is consistent reduction of oedema to regain and maintain functional benefit.
The ideal candidates for intravitreal fluocinolone acetonide are pseudophakic patients with DMO refractive to laser photocoagulation and anti-VEGF therapy. n
